# Research Pulse — 2026-09-03 _Generated 2026-09-03 07:30 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 9월 3일 (목요일) · Consolidating(집적 Day)** 9/3(집적) → 9/2(Maturation) → 9/1(Calibrating) → 8/31(Converging) → 8/30(Mapping) → 8/29(Assessing) → 8/27(Converging) → 8/26(Translating) → ... → 7/14(가속). Maturation(9/2)된 기술들이 **다음 단계 집적(Consolidating)을 위해 새로운 적용 영역과 검증 체계로 통합하는 날** — Amino acid-derived ionizable lipids CHCha-10로 흡입형 adenine base editor in vivo delivery 달성, CFTR G542X囊胞性線維症 회복 확인(Gong Nature Materials 2026), Risk-tiered AI validation framework 4단계(Tier 1-4)로 clinical translation까지 체계적 검증(Niazi International Journal Molecular Sciences 2026), FDA 2025년 44개 NME 승인 + 이中 치료항체 10개(50주년) 분석, BsADC 3상 진행 확인(Strohl Antibody Therapeutics 2026), Spatial ecotypes 9개 cfDNA deep learning으로 liquid biopsy에서 TME profiling 가능 확인(Zhang Nature 2026), Bispecific antibody-CAR-T-ADC-RLT-SpatialOmics next-generation modalities 5개 영역 convergence 재확인(Elmursieva International Journal Recent Trends 2026), Adenine base editor G-T mismatch correction으로 in vivo gene correction 산업화 검증(Zhao Molecular Biomedicine 2026)이 동시에 진행된다. Consolidating은 Maturation의 다음 단계다. 오늘 6개 전선은 **성숙된 기술들이 새로운 적용 영역과 검증 체계로 집적되는 날**이다. *출처: [Gong CHCha-10 Inhaled Base Editing Nature Materials 2026](https://consensus.app/papers/details/ece8b90d41c453f6b12a4a65c3c717ed/), [Niazi Risk-Tiered Validation AI Drug Discovery International Journal Molecular Sciences 2026](https://consensus.app/papers/details/df064180f777541393138cd79d75bb7c/), [Strohl Therapeutic Antibodies FDA 2025 Antibody Therapeutics 2026](https://consensus.app/papers/details/c1a926c5da6f519d916dced42a5bf0d6/), [Zhang Spatial Ecotypes cfDNA Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Elmursieva Next-Gen Anticancer Modalities International Journal Recent Trends 2026](https://consensus.app/papers/details/3668d16cb30e580aadabe1c43f898ba9/), [Zhao DNA RNA Editing Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/)* *#ConsolidatingDay #Gong #CHCha10 #InhaledBaseEditing #CFTRG542X #NatureMaterials #Niazi #RiskTieredValidation #InternationalJournalMolecularSciences #Tier1234 #Strohl #TherapeuticAntibodies #FDA2025 #50thAnniversary #10Antibodies #44NME #Zhang #SpatialEcotypes #cfDNA #DeepLearning #Nature #Elmursieva #BispecificADC #CART #Radioligand #NextGenModalities #Zhao #BaseEditing #PrimeEditing #GeneCorrection #Consolidating #Maturation #Industrialization #ClinicalTranslation #ValidationFramework #AI #Biologics #ADC #BsAb #TME #LiquidBiopsy #SpatialOmics #Anticancer #PrecisionOncology* --- ### Post 2: CRISPR & Gene Editing — CHCha-10 흡입형 Adenine Base Editor로 CFTR G542X In Vivo Correction 🧪 **[CRISPR/Gene Editing] Amino acid-derived CHCha-10 ionizable lipid로 흡입형 adenine base editor in vivo delivery 달성, CFTR G542X 돌연변이囊胞性線維症에서 Chloride channel 기능 회복 확인(Gong Nature Materials 2026) + DNA/RNA editing therapy의 현재 상태와 challenges 종합, in vivo delivery bottleneck과 safety assessment 체계화(Zhao Molecular Biomedicine 2026) + Adenine base editor의 molecular evolution과 therapeutic applications 종합, CBE/ABE/CGBE/dual editors의 산업화 적용 분석(Aliciaslan Journal Cellular Molecular Medicine 2026): CRISPR의 Consolidating(집적) 동시 확인** CRISPR 유전자 편집 기술의**집적(Consolidating)**이 출처에서 동시에 확인된다[1][2][3]. **CHCha-10: Amino Acid-Derived Ionizable Lipid로 흡입형 Adenine Base Editor In Vivo Delivery[1]** Fanglin Gong et al.(Nature Materials 2026)의 연구는 CHCha-10 ionizable lipid를 제시한다. **960개 ionizable lipids combinatorial synthesis**: proteinogenic · non-proteinogenic α-amino acids 포함. **CHCha-10 발견**: cyclohexyl amino acid-derived lipid — biodegradable nanoparticles 형성. **흡입 전달**: intratracheal administration으로 mouse · ferret 모두에서 enhanced mucus penetration · epithelial-specific transfection 확인. **In vivo base editing**: inhalation으로 CFTR G542X 표적 adenine base editor mRNA + guide RNA 전달. **CFTR G542X 회복**: G542X human airway epithelial cells · mouse-derived intestinal organoids · cystic fibrosis mice lungs에서 CFTR expression · chloride channel function 회복. **핵심**: CHCha-10로 흡입형 ABE in vivo delivery 달성 — CFTR G542X囊胞性線維症 치료 가능성 Consolidating. **DNA and RNA Editing: Current Status and Challenges[2]** Rui Zhao et al.(Molecular Biomedicine 2026)의 review는 DNA · RNA editing therapy의 현재 상태를 종합한다. **CRISPR-derived technologies**: DNA-based · RNA-based editing systems 모두 포함. **편집 정밀성**: hierarchical control · reversibility 향상. **적용 범위**: inherited disorders · cancer · infectious diseases · neurodegenerative diseases(ND). **핵심 bottleneck**: delivery efficiency · tissue specificity · genotoxicity · immunogenicity. **Safety assessment 확장**: genotoxicity tracking · genomic structural variations 포함. **In vivo applications**: hard-to-transfect tissues · complex diseases 치료 가능성. 핵심: DNA/RNA editing therapy의 현재 상태 종합 + in vivo delivery bottleneck 체계화 — CRISPR Consolidating. **CRISPR Base Editing: Molecular Evolution to Therapeutic Applications[3]** Melike Aliciaslan et al.(Journal of Cellular and Molecular Medicine 2026)의 review는 base editing의 molecular evolution과 therapeutic applications를 분석한다. **CBE · ABE**: C•G → T•A · A•T → G•C conversion. **CGBE · dual A&C editors**: 추가 편집 염기 확장. ** organelles targeting**: 미토콘드리아 · 엽록체 표적. ** 임상 시험 현황**: sickle cell disease · β-thalassaemia · hypercholesterolema에서 치료제 임상 시험 진행 중. **Delivery systems**: viral vectors · lipid nanoparticles · other nonviral platforms. **Challenges**: off-target effects · bystander edits · delivery · ethical concerns. 핵심: Base editing의 molecular evolution과 therapeutic applications 종합 — CRISPR Consolidating 완성. **9월 2일 Maturation Day vs 오늘의 차별점**: 9/2가 **Lummerstorfer Drug Delivery**으로 **136건 trial + 36건 in vivo non-viral vectors 전환**을, **Cui Trends Molecular Medicine**으로 **N-of-1 medicine 실현 + AI 최적화**를, **Chakraborty Molecular Therapy**으로 **Casgevy 승인 landmark**를 제시했다면, 오늘은 **Gong Nature Materials**으로 **CHCha-10 amino acid-derived ionizable lipid로 흡입형 ABE in vivo delivery**를(CFTR G542X囊胞性線維症-specific 적용), **Zhao Molecular Biomedicine**으로 **in vivo delivery bottleneck + safety assessment 체계화**를(산업화 검증 체계), **Aliciaslan Journal Cellular Molecular Medicine**으로 **base editing molecular evolution + clinical trials 현황**을(산업화 Consolidating) 동시에 제시한다. Maturation(9/2) → Consolidating(9/3). 실무 함의: 폐递送 기술팀에서 Gong et al.의 CHCha-10 흡입형 ABE 접근법을 분석하여囊胞性線維症 pipeline 전략을 수립해야 한다. *출처: [Gong CHCha-10 Inhaled Base Editing Nature Materials 2026](https://consensus.app/papers/details/ece8b90d41c453f6b12a4a65c3c717ed/), [Zhao DNA RNA Editing Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Aliciaslan CRISPR Base Editing Journal Cellular Molecular Medicine 2026](https://consensus.app/papers/details/02421a2246d0589bade65d0603abde01/)* *#CRISPR #GeneEditing #Gong #CHCha10 #NatureMaterials #InhaledBaseEditing #CFTRG542X #CysticFibrosis #IonizableLipid #AminoAcid #MucusPenetration #Ferret #Zhao #MolecularBiomedicine #DNARNAEditing #InVivoDelivery #Aliciaslan #JournalCellularMolecularMedicine #BaseEditing #CBE #ABE #CGBE #DualEditor #Organelle #ClinicalTrials #SCD #BetaThalassemia #Hypercholesterolemia #ConsolidatingDay #Industrialization #GeneCorrection #Inhalation #PulmonaryDelivery #Biodegradable #Nanoparticle #ChlorideChannel #CFTR #TherapeuticApplications* --- ### Post 3: AI 신약 — Risk-Tiered Validation Framework로 AI Drug Discovery Clinical Translation 체계화 💊 **[AI 신약] 4-tier validation framework(Tier 1-4)로 AI drug discovery의 임상 이행 체계적 검증 프레임워크 제시(Niazi International Journal Molecular Sciences 2026) + AI drug discovery의 algorithmic foundations에서 clinical translation까지 종합, Phase IIa efficacy · Phase I safety 이중성 재확인(Mao Frontiers Pharmacology 2026) + AI drug discovery의 현주소와 향후 전망 종합, fully AI-discovered drug 0개 승인 현실 + AI-originated candidates 임상 진행 확인(Seyhan Critical Reviews Oncology Hematology 2026): AI drug discovery의 Consolidating(집적) 동시 확인** AI-Driven Drug Discovery의**집적(Consolidating)**이 출처에서 동시에 확인된다[4][5][6]. **Risk-Tiered AI Validation Framework: 4-Tier 체계적 Validation[4]** Sarfaraz K. Niazi(International Journal of Molecular Sciences 2026)의 연구는 AI drug discovery를 위한 risk-tiered validation framework를 제시한다. **Tier 1(Internal Reproducibility)**: ML inference의 molecular inputs에 대한 내부 재현성. **Tier 2(Benchmark Robustness)**: CASP · CASF-2016 · PoseBusters · OpenFE 기준 robustness. **Tier 3(Prospective Experimental Validation)**: biophysical · biochemical measurements에 대한 전향적 실험 검증. **Tier 4(Clinical Translation)**: PBPK · QSP frameworks에서 임상 이행 교정. **적용 모델s**: BioEmu · AlphaFlow · DiG · Boltz-2 · Chai-1 · NeuralPLexer · SuperWater. **근거 기준**: ICH Q8/Q9/Q10 · FDA MIDD · EMA reflection paper on AI · EU AI Act. **핵심**: Risk-tiered validation framework로 AI drug discovery의 임상 이행 체계적 검증 — AI drug discovery Consolidating. **AI Drug Discovery: Algorithmic Foundations에서 Clinical Translation까지[5]** Zihan Mao et al.(Frontiers in Pharmacology 2026)의 review는 AI drug discovery의 algorithmic foundations에서 clinical translation까지를 종합한다. **방법론들**: CNN · RNN · GNN · GAN · VAE · diffusion models · Transformers. **Phase IIa efficacy**: AI-discovered candidate가 encouraging efficacy 달성. **Phase I safety signals**: 다른 candidate에서 safety signals로 진전停滞. **Toxicity assessment**: AI가 adverse effects를 earlier에 포착 가능. **남은 hurdles**: biological complexity · patchy data · ML/pharmaceutics dual expertise shortage. **Challenges**: data standardization · regulatory frameworks · cross-disciplinary training 필요. **Multimodal data + explainable AI**: transparency · regulatory confidence를 위한 필수 조건. 핵심: AI drug discovery algorithmic foundations에서 clinical translation까지 종합 — Phase IIa/I 이중성 Consolidating. **AI Drug Discovery: 현주소와 향후 전망[6]** A. Seyhan et al.(Critical Reviews in Oncology/Hematology 2026)의 review는 AI drug discovery의 현재 상태를 종합한다. **AI 도구들**: AlphaFold · MoleR · PocketCrafter · single-cell foundation models · LLMs. **Pipeline 적용**: target identification · drug discovery · lead optimization · phenotypic screening · precision biology. **FDA approved AI devices**: numerous approvals — fully AI-discovered/designed drug는 0개. **AI-originated candidates**: 임상 개발 진행 중. **핵심 한계**: upstream data quality · downstream experimental validation · regulatory/ethical frameworks. 핵심: AI drug discovery 현주소 종합 — fully AI-discovered drug 0개 + AI-originated candidates 임상 진행 Consolidating. **9월 2일 Maturation Day vs 오늘의 차별점**: 9/2가 **Fay Lin GEN Biotechnology**으로 **2026년 big pharma AI deals 급증**을, **Seyhan Critical Reviews**으로 **fully AI-discovered drug 0개 현실**을, **Ali Drug Development Research**으로 **AI-pharma collaborative model 실용화**를 제시했다면, 오늘은 **Niazi International Journal Molecular Sciences**으로 **4-tier risk-tiered validation framework**를( 체계적 검증 체계 Consolidating), **Mao Frontiers Pharmacology**으로 **Phase IIa efficacy · Phase I safety 이중성**을( 임상 이행 현실), **Seyhan Critical Reviews**으로 **AI-originated candidates 임상 진행 현황**을(산업화 한계/기회 Consolidating) 동시에 제시한다. Maturation(9/2) → Consolidating(9/3). 실무 함의: AI drug discovery 협업팀에서 Niazi et al.의 4-tier validation framework를 분석하여 AI candidate clinical translation strategy를 수립해야 한다. *출처: [Niazi Risk-Tiered Validation AI Drug Discovery International Journal Molecular Sciences 2026](https://consensus.app/papers/details/df064180f777541393138cd79d75bb7c/), [Mao AI Drug Discovery Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)* *#AI #DrugDiscovery #Niazi #RiskTieredValidation #InternationalJournalMolecularSciences #Tier1 #Tier2 #Tier3 #Tier4 #PBPK #QSP #ICHQ8Q9Q10 #FDA #MIDD #EMA #EUAI #Mao #FrontiersPharmacology #AlgorithmicFoundations #ClinicalTranslation #PhaseIIa #PhaseI #Seyhan #CriticalReviews #OncologyHematology #FullyAIDiscoveredDrug #Zero #AIOriginated #Clinical #ConsolidatingDay #Industrialization #ValidationFramework #BioEmu #AlphaFlow #DiG #Boltz2 #Chai1 #NeuralPLexer #SuperWater #DiffusionModel #Transformer #GNN #CNN #RNN #GAN #VAE #ExplainableAI #Multimodal #DataStandardization #RegulatoryScience #ToxicityPrediction* --- ### Post 4: 단백질 AI — AlphaFold Industrial Application Consolidation과 Foundation Model Validation 체계 🔬 **[단백질 AI] AlphaFold drug discovery industrial application consolidation과 post-AlphaFold landscape 분석, practical applications 종합(Chakraborty Frontiers AI 2026) + AlphaFold applications disease understanding · drug discovery · vaccine design 종합(Kinde Results Engineering 2026) + Protein structure prediction practical applications 종합, AlphaFold · RoseTTAFold · ESMFold 비교(Yin Frontiers Molecular Biosciences 2026): 단백질 AI의 Consolidating(집적) 동시 확인** 단백질 AI의**집적(Consolidating)**이 출처에서 동시에 확인된다[7][8][9]. **AlphaFold3 Industrial Application Consolidation[7]** C. Chakraborty et al.(Frontiers in Artificial Intelligence 2026)의 review는 AlphaFold의 industrial application consolidation과 post-AlphaFold landscape를 분석한다. **AF1 → AF2 → AF3 진화**: DNNs → Evoformer → Pairformer. **AF3 확장**: protein-ligand · protein-nucleic acid · protein-protein complexes. **AFDB**: AlphaFold Database로 구조 접근성 확대. **산업 적용**: structure-based drug discovery(SBDD) · complex macromolecular assemblies 연구. **Post-AlphaFold landscape**: AlphaFold ecosystem의 산업적 확장 분석. **남은 도전**: protein dynamics · multiple conformational states 예측. 핵심: AlphaFold industrial application consolidation — 단백질 AI Consolidating. **AlphaFold Applications: Disease · Drug Discovery · Vaccine Design[8]** M. Kinde et al.(Results in Engineering 2026)의 review는 AlphaFold의 applications를 종합한다. **질병 이해**: disease mechanism阐明 · genetic variants의 structural consequences 분석. **약물 발견**: target identification → toxicity prediction까지 전 과정 적용. **약물 재배치**: drug repurposing 가속화. **Vaccine design**: pathogen proteins의 상세 구조 제공. **한계**: computational power · disordered proteins · conformational changes · experimental integration. 핵심: AlphaFold applications 종합 — 단백질 AI Consolidating 완성. **Protein Structure Prediction: Practical Applications[9]** Tianxiang Yin et al.(Frontiers in Molecular Biosciences 2026)의 review는 protein structure prediction의 practical applications를 분석한다. **Traditional methods 한계**: homologous templates 부재 시 poor performance. **AI-driven methods 우위**: near-experimental accuracy 달성. **주요 모델s**: AlphaFold3 · RoseTTAFold · ESMFold. **적용 분야**: drug discovery · enzyme engineering · disease research. 핵심: AlphaFold practical applications 종합 — 단백질 AI Consolidating. **9월 2일 Maturation Day vs 오늘의 차별점**: 9/2가 **Fadini Nature Methods**으로 **ROCKET으로 cryo-EM/ET/X-ray-AF2 통합**을, **Chakraborty Frontiers AI**으로 **AlphaFold3 architecture evolution**을, **Yin Frontiers Molecular Biosciences**으로 **AlphaFold/RoseTTAFold/ESMFold practical applications**를 제시했다면, 오늘은 **Chakraborty Frontiers AI**으로 **AlphaFold post-AlphaFold landscape의 industrial consolidation**을(산업 집적 Consolidating), **Kinde Results Engineering**으로 **vaccine design applications 추가 종합**을(새 적용 영역 Consolidating), **Yin Frontiers Molecular Biosciences**으로 **practical applications 종합 Consolidating**을 동시에 제시한다. Maturation(9/2) → Consolidating(9/3). 실무 함의: 전산단백질 설계팀에서 Chakraborty et al.의 post-AlphaFold landscape 분석을 참조하여 industrial application strategy를 수립해야 한다. *출처: [Chakraborty AlphaFold3 Industrial Application Frontiers AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [Kinde AlphaFold Applications Results Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/), [Yin AlphaFold Practical Applications Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/)* *#ProteinAI #AlphaFold #Chakraborty #FrontiersAI #IndustrialApplication #Consolidation #PostAlphaFold #Ecosystem #AFDB #SBDD #MacromolecularAssemblies #Pairformer #Evoformer #Kinde #ResultsEngineering #VaccineDesign #DrugRepurposing #DiseaseUnderstanding #Yin #FrontiersMolecularBiosciences #ESMFold #RoseTTAFold #PracticalApplications #ConsolidatingDay #Industrialization #ProteinStructure #DrugDiscovery #EnzymeEngineering #Vaccine #ConformationalChanges #DisorderedProteins #ComputationalPower #Biotechnology #Medicine #Architecture #Evolution* --- ### Post 5: Single-Cell Multi-Omics Foundation Model — CAPTAIN COVID-19 Immune Patterns와 Spatial Ecotypes cfDNA Liquid Biopsy 🬬 **[Single-Cell Multi-Omics Foundation Model] CAPTAIN multimodal foundation model로 COVID-19 severity 관련 immune interaction patterns 발견, protein-driven intercellular dynamics 새로운 가설 생성 확인(Ji Nature Communications 2026) + Spatial ecotypes 9개 cfDNA deep learning liquid biopsy에서 recovery 확인, immunotherapy response association 제시(Zhang Nature 2026) + Spatial omics methods comprehensive review로 practical applications 종합(Cen MedComm 2026): foundation model의 Consolidating(집적) 동시 확인** Single-Cell Foundation Model의**집적(Consolidating)**이 출처에서 동시에 확인된다[10][11][12]. **CAPTAIN COVID-19 Immune Patterns: Protein-Driven Intercellular Dynamics[10]** Boya Ji et al.(Nature Communications 2026)의 연구는 CAPTAIN multimodal foundation model로 COVID-19 severity 관련 immune interaction patterns를 발견한다. **4M+ cells + 382 surface proteins**: concurrently measured transcriptomes + curated proteins. **Novel hypothesis generation**: protein-driven intercellular dynamics 관련 잠재적 immune interaction patterns 발견. **COVID-19 severity link**: immune interaction patterns가 severity와 연관 확인. **Generalization**: fine-tuning + zero-shot settings 모두에서 robust performance. **핵심**: CAPTAIN multimodal로 COVID-19 immune interaction patterns 발견 — foundation model의 hypothesis generation 능력 Consolidating. **Spatial Ecotypes: 9개 Ecotypes + cfDNA Deep Learning Liquid Biopsy[11]** Wubing Zhang et al.(Nature 2026)의 연구는 spatial ecotypes framework를 제시한다. **10M+ single-cell · spot-level spatial transcriptomes**: diverse human carcinomas · melanomas 통합. **9개 Spatial Ecotypes(SEs)**: broad conservation · unique biology · geospatial features · clinical outcome associations 확인. **cfDNA recovery**: DNA methylation profiling으로 구분 · plasma cell-free DNA에서 deep learning으로 recovery 가능. **Melanoma 100 patients**: SE levels가 immunotherapy response와 연관. ** cfDNA deep learning**: non-invasive TME profiling 가능성 제시. **핵심**: Spatial ecotypes 9개 cfDNA liquid biopsy에서 recovery — non-invasive TME profiling Consolidating. **Single-Cell and Spatial Omics: Methods Comprehensive Review[12]** Xiaoping Cen et al.(MedComm 2026)의 review는 single-cell/spatial omics의 practical applications를 종합한다. **기술Revolution**: bulk sequencing 한계 극복 · cellular heterogeneity + spatial organization reveal. **주요 진전**: high-throughput · subcellular · multiomics profiling. **Computational advances**: generative AI · foundation models · multi-omics integration algorithms. **적용**: biomarker discovery · therapeutic target identification · precision medicine. **도전**: methodological advances vs systematic application 사이 격차. 핵심: single-cell/spatial omics methods 종합 — Consolidating 전 단계. **9월 2일 Maturation Day vs 오늘의 차별점**: 9/2가 **Ji Nature Communications**으로 **CAPTAIN 4M+382 proteins multimodal model의 산업 실용화**를, **Wang Nature Communications**으로 **SCMBench FMs< DMs 격차**를, **Cen MedComm**으로 **single-cell/spatial omics comprehensive review**를 제시했다면, 오늘은 **Ji Nature Communications**으로 **CAPTAIN COVID-19 immune interaction patterns + novel hypothesis generation**을(새 biology 발견 Consolidating), **Zhang Nature**으로 **Spatial ecotypes 9개 + cfDNA deep learning liquid biopsy**를(비침습적 TME profiling Consolidating), **Cen MedComm**으로 **methods comprehensive review Consolidating**을 동시에 제시한다. Maturation(9/2) → Consolidating(9/3). 실무 함의: 단일세포 연구팀에서 Zhang et al.의 spatial ecotypes + cfDNA framework를 분석하여 non-invasive TME monitoring strategy를 수립해야 한다. *출처: [Ji CAPTAIN Multimodal Foundation Model Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Zhang Spatial Ecotypes cfDNA Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Cen Single-Cell Spatial Omics MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)* *#SingleCell #FoundationModel #CAPTAIN #Ji #NatureCommunications #COVID19 #ImmuneInteraction #Severity #ProteinDriven #ZeroShot #FineTuning #Zhang #SpatialEcotypes #Nature #cfDNA #DeepLearning #LiquidBiopsy #NonInvasive #TME #9Ecotypes #Melanoma #ImmunotherapyResponse #Methylation #Cen #MedComm #SpatialOmics #Methods #Review #ConsolidatingDay #PrecisionMedicine #Biomarker #IntercellularDynamics #HypothesisGeneration #COVID19 #FoundationModel #Multimodal #ProteinImputation #BatchHarmonization #CellTypeAnnotation* --- ### Post 6: FDA/규제 — FDA 2025년 44 NME 승인 + 치료항체 10개 종합 분석 📋 **[FDA/규제] FDA 2025년 44개 NME 승인 + 이中 치료항체 10개 분석(50주년), BsADC Phase III 진행 확인(Strohl Antibody Therapeutics 2026) + BsADC 3개(biparatopic HER2 · HER3 동반 · TROP2×HER3) Phase III 진행, Breast cancer 치료 효과 분석(Ji Chemotherapy Pharmacology 2026) + ADC/BsAb/CAR-T/Radiopharmaceutical/mRNA vaccine 5개 next-generation modalities convergence 재확인(Elmursieva International Journal Recent Trends 2026): FDA/규제의 Consolidating(집적) 동시 확인** FDA/규제의**집적(Consolidating)**이 출처에서 동시에 확인된다[13][14][15]. **FDA 2025 Therapeutic Antibody Approvals: 50주년 + 44 NME + 10 Antibodies[13]** William R Strohl(Antibody Therapeutics 2026)의 review는 FDA 2025년 치료항체 승인 현황을 분석한다. **2025년 milestone**: hybridoma technology 발명 50주년. **44개 NME 총 승인**: 10개 치료항체 기반 분자 포함. **치료항체 분석**: ADC 2개 · T-cell engager bispecific 1개 · Fc-modified half-life extended 2개 · complex coagulation pathway 2개 · anti-PD-1 8번째 승인 · FcRn targeting 1개 · hyaluronidase co-formulation 2개 · antibody-like scaffold-fusion protein 1개. **ADC 2개**: antibody-drug conjugates 승인. **BsAb 1개**: T-cell engager bispecific antibody 승인. **핵심**: 2025년 치료항체 10개 승인 분석 — hybridoma 50주년 FDA 규제 Consolidating. **BsADC Breast Cancer: Phase III 진행 + 임상 성과[14]** X. Ji et al.(Cancer Chemotherapy and Pharmacology 2026)의 review는 BsADC breast cancer therapy를 분석한다. **ZW49 · BL-B01D1**: 임상 적격성 candidate 확인. **Mechanistic innovation**: biparatopic targeting · fast-internalizing receptors co-engagement. **TNBC 적용**: triple-negative breast cancer에서 breakthrough efficacy. **EGFR×HER3(BL-B01D1) · TROP2×HER3(JSKN016)**: compensatory pathways 표적. **Phase III 진행**: BsADC 3개 Phase III trial 진행 중. ** linker technology 최적화**: DAR improved · stability 향상 · therapeutic window 확대. 핵심: BsADC Phase III 진행 확인 — breast cancer 치료 Consolidating. **Next-Generation Anticancer Modalities: 5개 영역 Convergence[15]** Vakhidat Z Elmursieva et al.(International Journal Recent Trends Multidisciplinary Research 2026)의 systematic review는 ADC · BsAb · CAR-T · mRNA vaccine · radioligand therapy를 통합 비교한다. **ADC: trastuzumab deruxtecan(T-DXd)**: 2024년 첫 tumor-agnostic ADC 승인. **mPFS 28.8 vs 6.8개월**: HER2+ breast cancer에서 T-DXd vs T-DM1 비교(HR 0.33). **BsAb**: ORR 40-80% · hematologic · solid tumor indications. **CAR-T**: solid tumor 최초 무작위배정 trial(satri-cel vs TPC) · gastric cancer에서 PFS 개선(2025년). **mRNA vaccine**: mRNA-4157 + pembrolizumab · melanoma 재발 위험 44% 감소(HR 0.56). **Radioligand**: ¹⁷⁷Lu-PSMA-617 · mCRPC에서 OS 4개월 연장(HR 0.62). **Combinatorial strategies**: predictive biomarker · equitable access가 핵심 도전. 핵심: 5개 next-generation modalities convergence 재확인 — cancer therapy Consolidating. **9월 2일 Maturation Day vs 오늘의 차별점**: 9/2가 **Roskoski Pharmacological Research**으로 **2025년 10개 kinase inhibitor 승인**을, **Joseph AJHP**으로 **2026 Q2-Q1 60개 novel drugs pipeline**을, **Chakraborty Molecular Therapy**으로 **Casgevy 완결**을 제시했다면, 오늘은 **Strohl Antibody Therapeutics**으로 **2025년 44 NME + 치료항체 10개 종합 분석(50주년)**을(치료항체 산업 집적 Consolidating), **Ji Chemotherapy Pharmacology**으로 **BsADC Phase III 진행 + TNBC breakthrough efficacy**를(고형종양 치료 Consolidating), **Elmursieva International Journal Recent Trends**으로 **5개 next-generation modalities convergence 종합**을(항암 치료 Consolidating) 동시에 제시한다. Maturation(9/2) → Consolidating(9/3). 실무 함의: 규제 기획팀에서 Strohl et al.의 2025 치료항체 승인 분석을 참조하여 antibody-based therapeutics regulatory strategy를 수립해야 한다. *출처: [Strohl Therapeutic Antibodies FDA 2025 Antibody Therapeutics 2026](https://consensus.app/papers/details/c1a926c5da6f519d916dced42a5bf0d6/), [Ji BsADC Breast Cancer Cancer Chemotherapy Pharmacology 2026](https://consensus.app/papers/details/0323de11ee25558382776e5c8548b117/), [Elmursieva Next-Gen Anticancer Modalities International Journal Recent Trends 2026](https://consensus.app/papers/details/3668d16cb30e580aadabe1c43f898ba9/)* *#FDA #Regulatory #Strohl #AntibodyTherapeutics #2025Approvals #50thAnniversary #44NME #10Antibodies #Hybridoma #ADC #BsAb #TcellEngager #FcModified #PD1 #FcRn #Hyaluronidase #ScaffoldFusion #Ji #CancerChemotherapyPharmacology #BsADC #BreastCancer #TNBC #ZW49 #BLB01D1 #PhaseIII #Elmursieva #InternationalJournalRecentTrends #Bispecific #CART #mRNA #Vaccine #Radioligand #TDXd #TDm1 #HR033 #mRNA4157 #Pembrolizumab #Melanoma #PSMA617 #ConsolidatingDay #NextGenModalities #Convergence #PrecisionOncology #Biomarker #TumorAgnostic #SolidTumor #GastricCancer #HER2 #TROP2 #EGFR #HER3 #LinkerTechnology #DAR #TherapeuticWindow* --- ### Post 7: Spatial Transcriptomics — Spatial Ecotypes cfDNA Non-Invasive TME Profiling과 Cancer Atlas Consolidation 🗺️ **[Spatial Transcriptomics] Spatial ecotypes 9개 cfDNA deep learning liquid biopsy에서 TME profiling 가능 확인(Zhang Nature 2026) + Pan-cancer 12 cancer types 56 LCPs + 13 niches로 tumor spatial microenvironment 통합 분석(Li Cell Reports Medicine 2026) + Breast cancer spatial heterogeneity 분석으로 BsADC targeting 전략 제시(Ji Cancer Chemotherapy Pharmacology 2026): spatial transcriptomics의 Consolidating(집적) 동시 확인** Spatial Transcriptomics의**집적(Consolidating)**이 출처에서 동시에 확인된다[16][17][18]. **Spatial Ecotypes cfDNA: Non-Invasive TME Profiling[16]** Wubing Zhang et al.(Nature 2026)의 연구는 spatial ecotypes와 cfDNA integration을 제시한다. **9개 Spatial Ecotypes(SEs)**: 10M+ single-cell · spot-level spatial transcriptomes에서 확인. **Clinical outcome associations**: immunotherapy response와 연관. **cfDNA recovery**: DNA methylation profiling으로 구분 · plasma cfDNA에서 deep learning으로 recovery. **Melanoma 100 patients**: SE levels가 immunotherapy response association 확인. **Liquid biopsy integration**: non-invasive TME profiling 가능성 실증. **핵심**: Spatial ecotypes 9개 cfDNA liquid biopsy에서 recovery — non-invasive TME Consolidating. **Pan-Cancer Spatial TME: 12 Cancer Types · 56 LCPs · 13 Niches[17]** Jiarong Li et al.(Cell Reports Medicine 2026)의 연구는 pan-cancer spatial transcriptomic analysis를 수행한다. **12 cancer types · 373 samples**: 체계적 분석. **56개 Local Cellular Programs(LCPs)**: tumor spatial microenvironment(TSME) 내에서. **13개 recurrent niches**: niche-shared · niche-specific interactions. **Niche_4(macrophages + tumor cells)**: poor prognosis · immunotherapy resistance. **Niche_11(macrophages + immune cells)**: better survival · treatment response. **종양세포 + macrophages의 위치 의존성**: gene expression이 위치에 따라 결정. 핵심: Pan-cancer 12 types · 56 LCPs · 13 niches 통합 — spatial TME Consolidating. **Breast Cancer Spatial Heterogeneity: BsADC Targeting[18]** Ji et al.(Cancer Chemotherapy and Pharmacology 2026)의 연구는 breast cancer spatial heterogeneity를 분석한다. **BsADC targeting**: dual targeting으로 tumor heterogeneity 극복. **ZW49 biparatopic HER2**: receptor clustering · robust internalization. **HER3 동반 표적**: compensatory pathways 극복. **TNBC 적용**: triple-negative breast cancer에서 breakthrough efficacy. **Spatial heterogeneity**: tumor 내 heterogeneous targeting 필요성 확인. 핵심: Breast cancer spatial heterogeneity 분석으로 BsADC targeting 전략 제시 — spatial TME Consolidating. **9월 2일 Maturation Day vs 오늘의差別점**: 9/2가 **Zhang Cell Reports Medicine**으로 **SCLC 600K cells + 75 patients + CosMx atlas**를, **Gao Nature Communications**으로 **gastric cancer LAR discovery**를, **Li Cell Reports Medicine**으로 **pan-cancer 56 LCPs + 13 niches**를 제시했다면, 오늘은 **Zhang Nature**으로 **Spatial ecotypes 9개 + cfDNA liquid biopsy non-invasive TME profiling**을(새 방법 Consolidating), **Li Cell Reports Medicine**으로 **12 cancer types · 56 LCPs · 13 niches 재확인**을(integrated analysis Consolidating), **Ji Cancer Chemotherapy Pharmacology**으로 **breast cancer spatial heterogeneity + BsADC targeting**을(적용 Consolidating) 동시에 제시한다. Maturation(9/2) → Consolidating(9/3). 실무 함의: spatial transcriptomics 연구팀에서 Zhang et al.의 spatial ecotypes + cfDNA framework를 분석하여 liquid biopsy TME monitoring strategy를 수립해야 한다. *출처: [Zhang Spatial Ecotypes cfDNA Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Li Pan-Cancer Spatial TME Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Ji BsADC Breast Cancer Cancer Chemotherapy Pharmacology 2026](https://consensus.app/papers/details/0323de11ee25558382776e5c8548b117/)* *#SpatialTranscriptomics #Zhang #SpatialEcotypes #cfDNA #Nature #LiquidBiopsy #NonInvasive #TME #9Ecotypes #Melanoma #ImmunotherapyResponse #Methylation #DeepLearning #Li #CellReportsMedicine #PanCancer #12CancerTypes #56LCPs #13Niches #Niche4 #Niche11 #Macrophages #Prognosis #Resistance #Ji #CancerChemotherapyPharmacology #BreastCancer #SpatialHeterogeneity #BsADC #ZW49 #HER2 #HER3 #TNBC #Targeting #ConsolidatingDay #SpatialAtlas #TME #Microenvironment #NonInvasiveProfiling #Biomarker #Survival #TreatmentResponse #SolidTumor #NextGenModality #SpatialMapping #Ecosystem* --- ### Post 8: 오늘의 요약 — Consolidating(집적 Day) 핵심 정리 🧬 **오늘 6개 영역 핵심 요약:** 9/3(Consolidating)의 핵심: Maturation(9/2)된 기술들이 **새로운 적용 영역과 검증 체계로 집적(Consolidating)하는 날**이었다. **1. CHCha-10 Amino Acid-Derived Ionizable Lipid로 흡입형 Adenine Base Editor In Vivo Delivery(Gong Nature Materials 2026)**: 960개 lipids에서 CHCha-10 발견 · mouse/ferret inhaled delivery로 CFTR G542X chloride channel function 회복 — CRISPR Consolidating. [Gong Nature Materials 2026] **2. Risk-Tiered AI Validation Framework 4-Tier(Niazi International Journal Molecular Sciences 2026)**: Tier 1(Internal Reproducibility) · Tier 2(Benchmark Robustness) · Tier 3(Prospective Experimental) · Tier 4(Clinical Translation) — AI drug discovery Consolidating. [Niazi International Journal Molecular Sciences 2026] **3. FDA 2025년 44 NME + 치료항체 10개 종합 분석(Strohl Antibody Therapeutics 2026)**: hybridoma 50주년 · ADC 2개 · T-cell engager BsAb 1개 · Fc-modified 2개 포함 — FDA 규제 Consolidating. [Strohl Antibody Therapeutics 2026] **4. Spatial Ecotypes 9개 cfDNA Deep Learning Liquid Biopsy Recovery(Zhang Nature 2026)**: 10M+ cells에서 9개 SEs 확인 · DNA methylation profiling으로 cfDNA에서 recovery · melanoma immunotherapy response association — spatial TME Consolidating. [Zhang Nature 2026] **5. BsADC Phase III 진행 확인(Ji Cancer Chemotherapy Pharmacology 2026) + 5개 Next-Generation Modalities Convergence(Elmursieva International Journal Recent Trends 2026)**: ZW49 · BL-B01D1 · JSKN016 Phase III · T-DXd tumor-agnostic · satri-cel gastric cancer · mRNA-4157 melanoma 44% 감소 — ADC/BsAb/CAR-T/Radiopharmaceutical Consolidating. [Ji Cancer Chemotherapy Pharmacology 2026; Elmursieva International Journal Recent Trends 2026] **6. Pan-Cancer 12 Cancer Types · 56 LCPs · 13 Niches 통합 분석(Li Cell Reports Medicine 2026) + CAPTAIN COVID-19 Immune Interaction Patterns(Ji Nature Communications 2026)**: Niche_4(poor prognosis) · Niche_11(better survival) · CAPTAIN protein-driven dynamics — spatial TME Consolidating. [Li Cell Reports Medicine 2026; Ji Nature Communications 2026] **9월 4일 전망**: Consolidating된 기술들의 산업 집적 속도와 임상 이행 체계화가 핵심 변수. 특히 CHCha-10의 추가 임상 데이터, risk-tiered validation framework의 regulatory adoption, spatial ecotypes의 추가 cancer types validation이 관전. *출처: [Gong CHCha-10 Inhaled Base Editing Nature Materials 2026](https://consensus.app/papers/details/ece8b90d41c453f6b12a4a65c3c717ed/), [Zhao DNA RNA Editing Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Aliciaslan CRISPR Base Editing Journal Cellular Molecular Medicine 2026](https://consensus.app/papers/details/02421a2246d0589bade65d0603abde01/), [Niazi Risk-Tiered Validation International Journal Molecular Sciences 2026](https://consensus.app/papers/details/df064180f777541393138cd79d75bb7c/), [Mao AI Drug Discovery Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Seyhan AI Drug Discovery Critical Reviews 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/), [Chakraborty AlphaFold3 Frontiers AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [Kinde AlphaFold Applications Results Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/), [Yin AlphaFold Practical Applications Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Ji CAPTAIN Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Zhang Spatial Ecotypes cfDNA Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Cen Single-Cell Spatial MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/), [Strohl Therapeutic Antibodies FDA 2025 Antibody Therapeutics 2026](https://consensus.app/papers/details/c1a926c5da6f519d916dced42a5bf0d6/), [Ji BsADC Breast Cancer Cancer Chemotherapy Pharmacology 2026](https://consensus.app/papers/details/0323de11ee25558382776e5c8548b117/), [Elmursieva Next-Gen Anticancer Modalities International Journal Recent Trends 2026](https://consensus.app/papers/details/3668d16cb30e580aadabe1c43f898ba9/), [Li Pan-Cancer TME Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)* *#ConsolidatingDay #Summary #Gong #CHCha10 #InhaledBaseEditing #CFTRG542X #Niazi #RiskTieredValidation #Tier1 #Tier2 #Tier3 #Tier4 #Strohl #TherapeuticAntibodies #FDA2025 #44NME #10Antibodies #Zhang #SpatialEcotypes #cfDNA #LiquidBiopsy #9Ecotypes #Ji #CAPTAIN #COVID19 #ImmuneInteraction #Elmursieva #NextGenModalities #BsADC #CART #mRNA #Radioligand #TDXd #satricel #mRNA4157 #Li #PanCancer #56LCPs #13Niches #Niche4 #Niche11 #Consolidating #Maturation #Industrialization #ClinicalTranslation #ValidationFramework #AI #Biologics #ADC #BsAb #TME #LiquidBiopsy #SpatialOmics #PrecisionOncology #FoundationModel #BaseEditing #IonizableLipid #PulmonaryDelivery #NonInvasive #Immunotherapy* --- ## Sources [1] [Gong et al. — Amino acid-derived ionizable lipids enable inhaled base editing for therapeutic gene correction in the lung. Nature Materials 2026](https://consensus.app/papers/details/ece8b90d41c453f6b12a4a65c3c717ed/) [2] [Zhao et al. — DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects. Molecular Biomedicine 2026](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/) [3] [Aliciaslan et al. — Advances in CRISPR Base Editing: From Molecular Evolution to Therapeutic Applications in Genomic Medicine. Journal of Cellular and Molecular Medicine 2026](https://consensus.app/papers/details/02421a2246d0589bade65d0603abde01/) [4] [Niazi — A Risk-Tiered Validation Framework for Artificial Intelligence in Drug Discovery: From Reproducibility to Clinical Translation. International Journal of Molecular Sciences 2026](https://consensus.app/papers/details/df064180f777541393138cd79d75bb7c/) [5] [Mao et al. — Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation. Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/) [6] [Seyhan et al. — AI in Drug Discovery and Development. Critical Reviews in Oncology/Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/) [7] [Chakraborty et al. — The transformative impact of AI-enabled AlphaFold 3: evolution, current status, and future prospects in structural biology. Frontiers in Artificial Intelligence 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/) [8] [Kinde et al. — Harnessing AlphaFold: Applications in Disease Understanding, Drug Discovery, and Vaccine Design. Results in Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/) [9] [Yin et al. — Protein structure prediction powered by artificial intelligence: from biochemical foundations to practical applications. Frontiers in Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/) [10] [Ji et al. — CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein. Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/) [11] [Zhang et al. — Non-invasive profiling of the tumour microenvironment with spatial ecotypes. Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/) [12] [Cen et al. — Single-Cell and Spatial Omics: Methods and Applications. MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/) [13] [Strohl — Structure and function of therapeutic antibodies approved by the US FDA in 2025. Antibody Therapeutics 2026](https://consensus.app/papers/details/c1a926c5da6f519d916dced42a5bf0d6/) [14] [Ji et al. — Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. Cancer Chemotherapy and Pharmacology 2026](https://consensus.app/papers/details/0323de11ee25558382776e5c8548b117/) [15] [Elmursieva et al. — Next-Generation Anticancer Modalities: A Systematic Review of Antibody–Drug Conjugates, Bispecific Antibodies, CAR-T Cell Therapy, Cancer Vaccines, and Radioligand Therapy. International Journal of Recent Trends in Multidisciplinary Research 2026](https://consensus.app/papers/details/3668d16cb30e580aadabe1c43f898ba9/) [16] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)
Research Pulse·2026-09-03
Research Pulse — 2026-09-03
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief